Literature DB >> 6824743

Targeting of N-(2-hydroxypropyl)methacrylamide copolymers to liver by incorporation of galactose residues.

R Duncan, J Kopecek, P Rejmanová, J B Lloyd.   

Abstract

Soluble synthetic polymers have potential as targetable carriers of pharmacological agents. Here we report that incorporation into poly[N-(2-hydroxypropyl)methacrylamide)] of an oligopeptide side-chain terminating in galactose enhanced the polymer's pinocytic uptake from the rat bloodstream by the liver. Within the liver lysosomes enzymic digestion led to the intracellular release of a drug analogue also bound to oligopeptide side-chains of the polymer.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6824743     DOI： 10.1016/0304-4165(83)90258-1

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN： 0006-3002


  11 in total

1.  Liver targeting of interferon through pullulan conjugation.

Authors:  K Xi; Y Tabata; K Uno; M Yoshimoto; T Kishida; Y Sokawa; Y Ikada
Journal:  Pharm Res       Date:  1996-12       Impact factor: 4.200

2.  The role of galactose, lactose, and galactose valency in the biorecognition of N-(2-hydroxypropyl)methacrylamide copolymers by human colon adenocarcinoma cells.

Authors:  Ayelet David; Pavla Kopecková; Jindrich Kopecek; Abraham Rubinstein
Journal:  Pharm Res       Date:  2002-08       Impact factor: 4.200

Review 3.  Beyond oncology--application of HPMA copolymers in non-cancerous diseases.

Authors:  Xin-Ming Liu; Scott C Miller; Dong Wang
Journal:  Adv Drug Deliv Rev       Date:  2009-11-10       Impact factor: 15.470

Review 4.  Polymer-drug conjugates: origins, progress to date and future directions.

Authors:  Jindřich Kopeček
Journal:  Adv Drug Deliv Rev       Date:  2012-11-02       Impact factor: 15.470

5.  HPMA copolymers: origins, early developments, present, and future.

Authors:  Jindrich Kopecek; Pavla Kopecková
Journal:  Adv Drug Deliv Rev       Date:  2009-11-14       Impact factor: 15.470

6.  N-(2-hydroxypropyl)methacrylamide copolymers targeted to the hepatocyte galactose-receptor: pharmacokinetics in DBA2 mice.

Authors:  L W Seymour; K Ulbrich; S R Wedge; I C Hume; J Strohalm; R Duncan
Journal:  Br J Cancer       Date:  1991-06       Impact factor: 7.640

7.  Comparison of the liver subcellular distribution of free daunomycin and that bound to galactosamine targeted N-(2-hydroxypropyl)methacrylamide copolymers, following intravenous administration in the rat.

Authors:  S R Wedge; R Duncan; P Kopeckova
Journal:  Br J Cancer       Date:  1991-04       Impact factor: 7.640

8.  Anticancer agents coupled to N-(2-hydroxypropyl)methacrylamide copolymers. I. Evaluation of daunomycin and puromycin conjugates in vitro.

Authors:  R Duncan; P Kopecková-Rejmanová; J Strohalm; I Hume; H C Cable; J Pohl; J B Lloyd; J Kopecek
Journal:  Br J Cancer       Date:  1987-02       Impact factor: 7.640

9.  Professor Tom Connors and the development of novel cancer therapies by the Phase I/II Clinical Trials Committee of Cancer Research UK.

Authors:  D R Newell; K M Searle; N B Westwood; S S Burtles
Journal:  Br J Cancer       Date:  2003-08-04       Impact factor: 7.640

10.  LEAPT: lectin-directed enzyme-activated prodrug therapy.

Authors:  Mark A Robinson; Stuart T Charlton; Philippe Garnier; Xiang-tao Wang; Stanley S Davis; Alan C Perkins; Malcolm Frier; Ruth Duncan; Tony J Savage; David A Wyatt; Susan A Watson; Benjamin G Davis
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-24       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.